Dr Reddy's Laboratories to launch Penicillamine capsules in US market

Dr Reddy’s Laboratories Ltd announced the launch of Penicillamine capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (Penicillamine) capsules, 250 mg, approved by United States Food & Drug Administration (USFDA) on Thursday.

Penicillamine USP is used in the treatment of Wilson’s disease. It is also used in reducing Cystine excretion in Cystinuria and also, to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy.

The Cuprimine brand and generic market had US sales of approximately $80 million MAT for the most recent twelve months ending in June 2020, according to IQVIA Health.

Penicillamine Capsules USP, for oral administration, contains 250 mg of penicillamine. Each capsule contains the following inactive ingredients: Black iron oxide, gelatin, microcrystalline cellulose, magnesium stearate, potassium hydroxide, propylene glycol, shellac, strong ammonia solution, and titanium dioxide. Dr Reddy’s Penicillamine capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.

The stock closed at 4429.05, down by 0.20 per cent or Rs 8.70 per share. The intraday high is Rs 4465.35 and the intraday low is Rs 4418. The 52-week high is 4754.30, while the 52-week low is 2495.40.